<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118739</url>
  </required_header>
  <id_info>
    <org_study_id>D5495C00007</org_study_id>
    <nct_id>NCT03118739</nct_id>
  </id_info>
  <brief_title>Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria</brief_title>
  <official_title>Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to evaluate signals of potential clinical
      benefit of the combination of Verinurad and Febuxostat in lowering concentrations of
      circulating uric acid and thus improving kidney or cardiovascular status of patients with
      hyperuricemia, albuminuria, and Type 2 diabetes (T2DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence shows independent associations between elevated serum uric acid (sUA) and the risk
      of hypertension, myocardial infarction (MI), chronic kidney disease (CKD), T2DM, heart
      failure (HF), and metabolic syndrome, including obesity. Gout is associated with an increased
      risk of all-cause death, as well as cardiovascular death. The causal relationship between
      elevated sUA, gout, and these disease outcomes remains to be proven.

      Verinurad (RDEA3170), is a novel Urate Transporter 1 (URAT1) inhibitor in Phase II
      development. Verinurad combined with the xanthine oxidase (XO) inhibitor febuxostat has been
      shown to lower sUA in patients with recurrent gout in Phase II studies by &gt;80%. The extensive
      lowering of sUA delivered by the combination presents a unique opportunity to explore whether
      intensive urate lowering therapy can improve kidney and/or cardiac health.

      This study will assess if intensive serum urate lowering therapy, more potent than ever
      explored before in the chronic out-patient setting, can improve chronic kidney or cardiac
      function in the study population.

      In order to maximize the scientific value of the study and minimize the risk for systemic
      biases a parallel group, double blind, randomized design will be utilized.

      The study will recruit patients with hyperuricemia and presenting with albuminuria.

      Hyperuricemic patients are expected to benefit more from urate lowering, and albuminuria at
      baseline is required, as the primary objective of the study will be to assess changes in
      albuminuria.

      Patients are also required to be diagnosed with T2DM. Patients with T2DM frequently exhibit
      changes in cardiac function detectable using magnetic resonance imaging (MRI) that represents
      an early, pre-symptomatic state of HF. By limiting recruitment to patients with T2DM and by
      performing MRI at baseline and 6 months of therapy, the study will deliver insights into
      whether or not intensive urate lowering therapy can positively affect not only chronic kidney
      disease, but also cardiac disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 2017</start_date>
  <completion_date type="Actual">August 13, 2018</completion_date>
  <primary_completion_date type="Actual">August 13, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, double-dummy, placebo-controlled, parallel, independent groups, repeated measures, multi-center study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Verinurad capsules/matching placebo capsules and febuxostat/matching placebo capsules with randomization code printed on each label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Albumin to Creatinine Ratio (UACR)</measure>
    <time_frame>From Baseline to 12 Weeks of Treatment</time_frame>
    <description>LS Mean Percentage Change (95% CI) from Baseline in UACR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Albumin to Creatinine Ratio (UACR) Compared to Placebo</measure>
    <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
    <description>LS Mean Percentage Change (90% CI) from Baseline in UACR Compared to Placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Albumin to Creatinine Ratio (UACR)</measure>
    <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
    <description>LS Mean Percentage Change (95% CI) from Baseline in UACR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sUA</measure>
    <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
    <description>LS Mean Percentage Change (95% CI) from Baseline in sUA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR</measure>
    <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
    <description>LS Mean Percentage Change (95% CI) from Baseline in eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
    <description>LS Mean Percentage Change (95% CI) from Baseline in Serum Creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Cystatin C</measure>
    <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
    <description>LS Mean Percentage Change (95% CI) from Baseline in Serum Cystatin C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum High Sensitivity C-reactive Protein</measure>
    <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
    <description>LS Mean Percentage Change (95% CI) from Baseline in Serum High Sensitivity C-reactive Protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Assessments</measure>
    <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
    <description>Change from Baseline in Diastolic and Systolic Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Variables - LV Mass/End-diastolic Volume</measure>
    <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
    <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Variables - Kidney Cortex T2 Star - BOLD MRI</measure>
    <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
    <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Variables - LV End-diastolic Volume, LV End-systolic Volume, LV Stroke Volume</measure>
    <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
    <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Variables - LV Ejection Fraction, Circumferential Strain, Longitudinal Strain, Radial Strain</measure>
    <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
    <description>Change from baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Variables - Diastolic Circumferential Strain Rate, Longitudinal Strain Rate, Radial Strain Rate and Systolic Circumferential Strain Rate, Longitudinal Strain Rate, Radial Strain Rate</measure>
    <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
    <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Variables - LV Mass</measure>
    <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
    <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Flow Mediated Dilatation (Reactive Hyperemia)</measure>
    <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
    <description>LS Mean Change (95% CI) from Baseline in Flow Mediated Dilatation. The flow mediated dilatation metric is obtained using a device from Cordex, and a proprietary algorithm.
This metric represents the volume difference between a baseline arterial compliance curve and hyperemia arterial compliance curve in the positive transmural pressure region. This metric has a direct relationship to a subject's cardiovascular condition. Output range is 0-150. A higher score is indicative of a better flow mediated dilatation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Urinalysis</measure>
    <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
    <description>Changes in Urinalysis (CFB = Change from Baseline)</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Chemistry Values</measure>
    <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
    <description>Changes in Clinical Chemistry Values (CFB = Change for Baseline)</description>
  </other_outcome>
  <other_outcome>
    <measure>Baseline eGFR</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline UACR</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline Serum Uric Acid (sUA)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline Serum Creatinine</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline Serum Cystatin-C</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline Serum High-sensitivity C-reactive Protein</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - Kidney Cortex T2 Star</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - LV End-diastolic Volume</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - LV Ejection Fraction</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - LV End-systolic Volume</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - Circumferential Strain</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - Diastolic Circumferential Strain Rate</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - Diastolic Longitudinal Strain Rate</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - Diastolic Radial Strain Rate</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - Longitudinal Strain</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - Radial Strain</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - Systolic Circumferential Strain Rate</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - Systolic Longitudinal Strain Rate</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - Systolic Radial Strain Rate</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - LV Mass</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - LV Mass/End-diastolic Volume</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline MRI Variables - LV Stroke Volume</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Baseline Flow Mediated Dilatation (Reactive Hyperemia)</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline in Flow Mediated Dilatation. The flow mediated dilatation metric is obtained using a device from Cordex, and a proprietary algorithm.
This metric represents the volume difference between a baseline arterial compliance curve and hyperemia arterial compliance curve in the positive transmural pressure region. This metric has a direct relationship to a subject's cardiovascular condition. Output range is 0-150. A higher score is indicative of a better flow mediated dilatation.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Albuminuria</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Verinurad 9 mg+Febuxostat 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule administered orally, once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule administered orally, once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verinurad 9 mg+Febuxostat 80 mg</intervention_name>
    <description>Capsule administered orally, once daily for 24 weeks</description>
    <arm_group_label>Verinurad 9 mg+Febuxostat 80 mg</arm_group_label>
    <other_name>Verinurad (RDEA3170), Febuxostat(Uloric)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule administered orally, once daily for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serum Uric Acid ≥6.0 mg/dL

          -  eGFR ≥30 mL/min/1.73 m2

          -  UACR between 30 mg/g and 3500 mg/g inclusive

          -  Diagnosed with T2DM

        Exclusion Criteria:

          -  Treated with any drug for hyperuricemia in the 6 months preceding randomization.Drugs
             for hyperuricemia include all XO inhibitors (allopurinol, febuxostat and topiroxostat)
             and URAT1 inhibitors (lesinurad, verinurad, probenecid, and benzbromarone)

          -  Prior history of gout, unless prophylaxis therapy isn't required

          -  Patients who are pregnant, lactating, or planning to become pregnant

          -  Patients unsuitable or unable to undergo MRI assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canyon Country</city>
        <state>California</state>
        <zip>91351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056-4510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D5495C00007&amp;amp;attachmentIdentifier=7ba9d99a-a3d8-4550-9897-42c1821775ff&amp;amp;fileName=d5495c00007_csp_Redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>Redacted Protocol</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D5495C00007&amp;amp;attachmentIdentifier=fe54e85c-c086-4dca-89de-900472089931&amp;amp;fileName=d5495c00007_sap_Redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>redacted SAP</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <results_first_submitted>July 15, 2019</results_first_submitted>
  <results_first_submitted_qc>December 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 10, 2020</results_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
    <mesh_term>Verinurad</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data (IPD) will likely not be shared with external collaborators/researchers as this data is planned to be used only for internal decision-making</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03118739/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 19 clinical research centers in the United States of America. First subject enrolled (First subject first visit/first consent signed date): 18 May 2017. Last subject last visit: 13 August 2018.</recruitment_details>
      <pre_assignment_details>Patients were screened at Visit 1. Within 1 week, eligible patients collected 3 morning void samples on consecutive days for proteinuria measurements. Patients with acceptable results were scheduled for Visit 2. Prior to randomization and before or on the day of Visit 2, patients underwent MRI. V2 occurred no later than 6 weeks after V1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Verinurad 9 mg+Febuxostat 80 mg</title>
          <description>Capsule administered orally, once daily for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Capsule administered orally, once daily for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 12 Weeks of Treatment</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 24 Weeks of Treatment</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Verinurad 9 mg+Febuxostat 80 mg</title>
          <description>Capsule administered orally, once daily for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Capsule administered orally, once daily for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at Randomization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age at Screening</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.0" spread="9.51"/>
                    <measurement group_id="B2" value="60.9" spread="12.15"/>
                    <measurement group_id="B3" value="61.5" spread="10.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.72" spread="20.243"/>
                    <measurement group_id="B2" value="96.76" spread="19.561"/>
                    <measurement group_id="B3" value="95.14" spread="19.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.57" spread="10.662"/>
                    <measurement group_id="B2" value="170.75" spread="9.117"/>
                    <measurement group_id="B3" value="170.65" spread="9.888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.00" spread="5.082"/>
                    <measurement group_id="B2" value="32.95" spread="4.699"/>
                    <measurement group_id="B3" value="32.44" spread="4.889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>estimated glomerular filtration rate (eGFR)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>eGFR&lt;30</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>eGFR &gt;=30 to &lt;60</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>eGFR &gt;=60 to &lt;90</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>eGFR &gt;=90</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Albumin to Creatinine Ratio (UACR)</title>
        <description>LS Mean Percentage Change (95% CI) from Baseline in UACR</description>
        <time_frame>From Baseline to 12 Weeks of Treatment</time_frame>
        <population>Number analyzed at 12 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Albumin to Creatinine Ratio (UACR)</title>
          <description>LS Mean Percentage Change (95% CI) from Baseline in UACR</description>
          <population>Number analyzed at 12 weeks was less than the overall number analyzed due to missing observations</population>
          <units>Precent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.65" lower_limit="-64.807" upper_limit="-25.089"/>
                    <measurement group_id="O2" value="-15.31" lower_limit="-43.244" upper_limit="26.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean % Change from Baseline</param_type>
            <param_value>-39.37</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.785</ci_lower_limit>
            <ci_upper_limit>-3.814</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>sUA</title>
        <description>LS Mean Percentage Change (95% CI) from Baseline in sUA</description>
        <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>sUA</title>
          <description>LS Mean Percentage Change (95% CI) from Baseline in sUA</description>
          <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.81" lower_limit="-63.879" upper_limit="-48.350"/>
                    <measurement group_id="O2" value="6.86" lower_limit="-11.800" upper_limit="29.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.93" lower_limit="-68.274" upper_limit="-54.319"/>
                    <measurement group_id="O2" value="4.73" lower_limit="-13.795" upper_limit="27.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>eGFR</title>
        <description>LS Mean Percentage Change (95% CI) from Baseline in eGFR</description>
        <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>eGFR</title>
          <description>LS Mean Percentage Change (95% CI) from Baseline in eGFR</description>
          <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="-6.520" upper_limit="9.674"/>
                    <measurement group_id="O2" value="-4.40" lower_limit="-12.258" upper_limit="4.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.73" lower_limit="-9.446" upper_limit="6.648"/>
                    <measurement group_id="O2" value="0.55" lower_limit="-7.854" upper_limit="9.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Creatinine</title>
        <description>LS Mean Percentage Change (95% CI) from Baseline in Serum Creatinine</description>
        <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine</title>
          <description>LS Mean Percentage Change (95% CI) from Baseline in Serum Creatinine</description>
          <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" lower_limit="-6.946" upper_limit="6.188"/>
                    <measurement group_id="O2" value="3.44" lower_limit="-3.636" upper_limit="11.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" lower_limit="-4.743" upper_limit="9.078"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-6.945" upper_limit="7.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Cystatin C</title>
        <description>LS Mean Percentage Change (95% CI) from Baseline in Serum Cystatin C</description>
        <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Cystatin C</title>
          <description>LS Mean Percentage Change (95% CI) from Baseline in Serum Cystatin C</description>
          <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.252" lower_limit="-1.3402" upper_limit="8.0581"/>
                    <measurement group_id="O2" value="0.114" lower_limit="-4.6520" upper_limit="5.1187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.412" lower_limit="0.5212" upper_limit="10.5418"/>
                    <measurement group_id="O2" value="3.951" lower_limit="-1.1612" upper_limit="9.3279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum High Sensitivity C-reactive Protein</title>
        <description>LS Mean Percentage Change (95% CI) from Baseline in Serum High Sensitivity C-reactive Protein</description>
        <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serum High Sensitivity C-reactive Protein</title>
          <description>LS Mean Percentage Change (95% CI) from Baseline in Serum High Sensitivity C-reactive Protein</description>
          <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.863" lower_limit="4.5883" upper_limit="76.4884"/>
                    <measurement group_id="O2" value="11.665" lower_limit="-15.6408" upper_limit="47.8091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.002" lower_limit="-29.9761" upper_limit="20.8680"/>
                    <measurement group_id="O2" value="9.793" lower_limit="-17.8132" upper_limit="46.6716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Assessments</title>
        <description>Change from Baseline in Diastolic and Systolic Blood Pressure</description>
        <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Assessments</title>
          <description>Change from Baseline in Diastolic and Systolic Blood Pressure</description>
          <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>mm/Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diastolic BP, mmHg Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" spread="9.83"/>
                    <measurement group_id="O2" value="77.8" spread="11.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP, mmHg 12 weeks (Change from baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="11.02"/>
                    <measurement group_id="O2" value="-0.2" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP, mmHg 24 weeks (Change from baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="8.53"/>
                    <measurement group_id="O2" value="1.7" spread="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP, mmHg Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.4" spread="15.13"/>
                    <measurement group_id="O2" value="138.5" spread="16.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP, mmHg 12 weeks (Change from baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="19.00"/>
                    <measurement group_id="O2" value="-3.2" spread="15.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP, mmHg 24 weeks (Change from baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="9.75"/>
                    <measurement group_id="O2" value="-0.6" spread="17.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRI Variables - LV Mass/End-diastolic Volume</title>
        <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
        <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Variables - LV Mass/End-diastolic Volume</title>
          <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
          <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>g/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049" spread="0.1445"/>
                    <measurement group_id="O2" value="0.053" spread="0.1202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Flow Mediated Dilatation (Reactive Hyperemia)</title>
        <description>LS Mean Change (95% CI) from Baseline in Flow Mediated Dilatation. The flow mediated dilatation metric is obtained using a device from Cordex, and a proprietary algorithm.
This metric represents the volume difference between a baseline arterial compliance curve and hyperemia arterial compliance curve in the positive transmural pressure region. This metric has a direct relationship to a subject's cardiovascular condition. Output range is 0-150. A higher score is indicative of a better flow mediated dilatation.</description>
        <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Flow Mediated Dilatation (Reactive Hyperemia)</title>
          <description>LS Mean Change (95% CI) from Baseline in Flow Mediated Dilatation. The flow mediated dilatation metric is obtained using a device from Cordex, and a proprietary algorithm.
This metric represents the volume difference between a baseline arterial compliance curve and hyperemia arterial compliance curve in the positive transmural pressure region. This metric has a direct relationship to a subject's cardiovascular condition. Output range is 0-150. A higher score is indicative of a better flow mediated dilatation.</description>
          <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 weeks Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-10.59" upper_limit="12.24"/>
                    <measurement group_id="O2" value="-5.9" lower_limit="-17.04" upper_limit="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-9.44" upper_limit="10.47"/>
                    <measurement group_id="O2" value="-5.5" lower_limit="-15.47" upper_limit="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Urinalysis</title>
        <description>Changes in Urinalysis (CFB = Change from Baseline)</description>
        <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Urinalysis</title>
          <description>Changes in Urinalysis (CFB = Change from Baseline)</description>
          <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Protein, mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.01" spread="99.767"/>
                    <measurement group_id="O2" value="65.74" spread="78.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, mg/dL 12 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.40" spread="65.896"/>
                    <measurement group_id="O2" value="-4.07" spread="71.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, mg/dL 24 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.73" spread="101.052"/>
                    <measurement group_id="O2" value="11.40" spread="76.645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Urine Albumin, mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0907" spread="55.62178"/>
                    <measurement group_id="O2" value="35.8905" spread="47.17446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Albumin, mg/dL 12 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4766" spread="35.73442"/>
                    <measurement group_id="O2" value="-0.3019" spread="45.81688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Albumin, mg/dL 24 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9482" spread="50.66844"/>
                    <measurement group_id="O2" value="11.6049" spread="53.13042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Urine Creatinine, mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.52" spread="51.570"/>
                    <measurement group_id="O2" value="86.25" spread="46.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Creatinine, mg/dL 12 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="53.378"/>
                    <measurement group_id="O2" value="12.95" spread="34.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Creatinine, mg/dL 24 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.58" spread="55.930"/>
                    <measurement group_id="O2" value="8.53" spread="36.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Urine Urate, mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.354" spread="12.0591"/>
                    <measurement group_id="O2" value="23.960" spread="10.6862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Urate, mg/dL 12 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.394" spread="13.2757"/>
                    <measurement group_id="O2" value="3.560" spread="12.3875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Urate, mg/dL 24 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.732" spread="16.4720"/>
                    <measurement group_id="O2" value="2.294" spread="9.3407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Chemistry Values</title>
        <description>Changes in Clinical Chemistry Values (CFB = Change for Baseline)</description>
        <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Values</title>
          <description>Changes in Clinical Chemistry Values (CFB = Change for Baseline)</description>
          <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Aldosterone, pmol/L</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.58" spread="126.126"/>
                    <measurement group_id="O2" value="95.11" spread="72.640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone, pmol/L 12 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="118.622"/>
                    <measurement group_id="O2" value="14.72" spread="72.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone, pmol/L 24 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.14" spread="102.932"/>
                    <measurement group_id="O2" value="38.14" spread="90.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline NT-proBNP, pmol/L</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.230" spread="22.6864"/>
                    <measurement group_id="O2" value="15.866" spread="28.2147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NT-proBNP, pmol/L 12 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.621" spread="31.1027"/>
                    <measurement group_id="O2" value="1.556" spread="10.0140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NT-proBNP, pmol/L 24 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.267" spread="19.0367"/>
                    <measurement group_id="O2" value="15.866" spread="46.4392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary Albumin to Creatinine Ratio (UACR) Compared to Placebo</title>
        <description>LS Mean Percentage Change (90% CI) from Baseline in UACR Compared to Placebo</description>
        <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Albumin to Creatinine Ratio (UACR) Compared to Placebo</title>
          <description>LS Mean Percentage Change (90% CI) from Baseline in UACR Compared to Placebo</description>
          <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>Precent change</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.26" lower_limit="-68.206" upper_limit="-19.009"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">The primary endpoint is a comparison</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRI Variables - Kidney Cortex T2 Star - BOLD MRI</title>
        <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
        <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Variables - Kidney Cortex T2 Star - BOLD MRI</title>
          <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
          <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="6.511"/>
                    <measurement group_id="O2" value="-1.67" spread="6.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRI Variables - LV End-diastolic Volume, LV End-systolic Volume, LV Stroke Volume</title>
        <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
        <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Variables - LV End-diastolic Volume, LV End-systolic Volume, LV Stroke Volume</title>
          <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
          <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LV End-diastolic Volume (mL) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.39" spread="27.458"/>
                    <measurement group_id="O2" value="-4.93" spread="20.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV End-systolic Volume (mL) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="14.106"/>
                    <measurement group_id="O2" value="-2.48" spread="10.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV Stroke Volume (mL) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.73" spread="15.923"/>
                    <measurement group_id="O2" value="-2.44" spread="12.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRI Variables - LV Ejection Fraction, Circumferential Strain, Longitudinal Strain, Radial Strain</title>
        <description>Change from baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
        <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Variables - LV Ejection Fraction, Circumferential Strain, Longitudinal Strain, Radial Strain</title>
          <description>Change from baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
          <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>% (change in percentage from baseline)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LV Ejection Fraction (%) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="3.761"/>
                    <measurement group_id="O2" value="0.59" spread="3.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circumferential Strain (%) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="2.321"/>
                    <measurement group_id="O2" value="-0.07" spread="2.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Longitudinal Strain (%) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="1.949"/>
                    <measurement group_id="O2" value="0.53" spread="1.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radial Strain (%) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="7.136"/>
                    <measurement group_id="O2" value="1.44" spread="8.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRI Variables - Diastolic Circumferential Strain Rate, Longitudinal Strain Rate, Radial Strain Rate and Systolic Circumferential Strain Rate, Longitudinal Strain Rate, Radial Strain Rate</title>
        <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
        <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Variables - Diastolic Circumferential Strain Rate, Longitudinal Strain Rate, Radial Strain Rate and Systolic Circumferential Strain Rate, Longitudinal Strain Rate, Radial Strain Rate</title>
          <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
          <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>s^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diastolic Circumferential Strain Rate (s^-1) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0496" spread="0.13769"/>
                    <measurement group_id="O2" value="-0.0384" spread="0.13791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Longitudinal Strain Rate (s^-1) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0043" spread="0.10629"/>
                    <measurement group_id="O2" value="-0.0300" spread="0.16940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Radial Strain Rate (s^-1) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2348" spread="0.43676"/>
                    <measurement group_id="O2" value="0.0201" spread="0.72927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Circumferential Strain Rate (s^-1) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0115" spread="0.11314"/>
                    <measurement group_id="O2" value="-0.0743" spread="0.11616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Longitudinal Strain Rate (s^-1) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0285" spread="0.08436"/>
                    <measurement group_id="O2" value="-0.0021" spread="0.08052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Radial Strain Rate (s^-1) (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1917" spread="0.31833"/>
                    <measurement group_id="O2" value="0.2516" spread="0.38049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRI Variables - LV Mass</title>
        <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
        <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Variables - LV Mass</title>
          <description>Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline)</description>
          <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="7.532"/>
                    <measurement group_id="O2" value="2.63" spread="9.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Urinalysis</title>
        <description>Changes in Urinalysis (CFB = Change from Baseline)</description>
        <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Urinalysis</title>
          <description>Changes in Urinalysis (CFB = Change from Baseline)</description>
          <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Protein/Creatinine, mg/g</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="945.56" spread="1457.714"/>
                    <measurement group_id="O2" value="828.52" spread="987.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein/Creatinine, mg/g 12 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-185.33" spread="366.340"/>
                    <measurement group_id="O2" value="-155.44" spread="584.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein/Creatinine, mg/g 24 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-98.60" spread="397.778"/>
                    <measurement group_id="O2" value="177.11" spread="1387.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Chemistry Values</title>
        <description>Changes in Clinical Chemistry Values (CFB = Change for Baseline)</description>
        <time_frame>From Baseline to 12 Weeks and 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Values</title>
          <description>Changes in Clinical Chemistry Values (CFB = Change for Baseline)</description>
          <population>Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>% hemoglobin bound to glucose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Hemoglobin A1C/Hemoglobin, %</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.14" spread="1.913"/>
                    <measurement group_id="O2" value="8.28" spread="2.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin A1C/Hemoglobin, % 12 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="1.399"/>
                    <measurement group_id="O2" value="0.13" spread="1.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin A1C/Hemoglobin, % 24 weeks (CFB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.884"/>
                    <measurement group_id="O2" value="0.22" spread="1.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline eGFR</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline eGFR</title>
          <units>mL/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" spread="25.25"/>
                    <measurement group_id="O2" value="68.1" spread="23.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline UACR</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline UACR</title>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459.05" spread="824.731"/>
                    <measurement group_id="O2" value="411.55" spread="547.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline Serum Uric Acid (sUA)</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Serum Uric Acid (sUA)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" spread="1.558"/>
                    <measurement group_id="O2" value="7.02" spread="0.813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline Serum Creatinine</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Serum Creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.595"/>
                    <measurement group_id="O2" value="1.19" spread="0.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline Serum Cystatin-C</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Serum Cystatin-C</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.579" spread="0.5274"/>
                    <measurement group_id="O2" value="1.313" spread="0.3532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline Serum High-sensitivity C-reactive Protein</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Serum High-sensitivity C-reactive Protein</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.410" spread="0.3670"/>
                    <measurement group_id="O2" value="0.358" spread="0.2506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - Kidney Cortex T2 Star</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - Kidney Cortex T2 Star</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.13" spread="12.995"/>
                    <measurement group_id="O2" value="82.31" spread="11.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - LV End-diastolic Volume</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - LV End-diastolic Volume</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.47" spread="37.766"/>
                    <measurement group_id="O2" value="161.50" spread="32.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - LV Ejection Fraction</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - LV Ejection Fraction</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>% (percentage of LV volume)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.77" spread="7.869"/>
                    <measurement group_id="O2" value="60.19" spread="6.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - LV End-systolic Volume</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - LV End-systolic Volume</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.43" spread="26.089"/>
                    <measurement group_id="O2" value="64.63" spread="17.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - Circumferential Strain</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - Circumferential Strain</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>% (change in percentage in LV dimension)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.10" spread="3.925"/>
                    <measurement group_id="O2" value="-15.37" spread="2.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - Diastolic Circumferential Strain Rate</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - Diastolic Circumferential Strain Rate</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>s^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6371" spread="0.24946"/>
                    <measurement group_id="O2" value="0.7588" spread="0.21276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - Diastolic Longitudinal Strain Rate</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - Diastolic Longitudinal Strain Rate</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>s^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4833" spread="0.21090"/>
                    <measurement group_id="O2" value="0.5258" spread="0.16476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - Diastolic Radial Strain Rate</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - Diastolic Radial Strain Rate</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>s^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3143" spread="1.08926"/>
                    <measurement group_id="O2" value="-2.7591" spread="1.05712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - Longitudinal Strain</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - Longitudinal Strain</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>% (change in percentage in LV dimension)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.07" spread="3.779"/>
                    <measurement group_id="O2" value="-12.21" spread="3.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - Radial Strain</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - Radial Strain</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>% (change in percentage in LV dimension)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.47" spread="15.943"/>
                    <measurement group_id="O2" value="46.45" spread="12.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - Systolic Circumferential Strain Rate</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - Systolic Circumferential Strain Rate</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>s^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7673" spread="0.19408"/>
                    <measurement group_id="O2" value="-0.7797" spread="0.12776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - Systolic Longitudinal Strain Rate</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - Systolic Longitudinal Strain Rate</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>s^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6278" spread="0.16784"/>
                    <measurement group_id="O2" value="-0.6552" spread="0.12734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - Systolic Radial Strain Rate</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - Systolic Radial Strain Rate</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>s^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1059" spread="0.66890"/>
                    <measurement group_id="O2" value="2.1220" spread="0.58484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - LV Mass</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - LV Mass</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.27" spread="26.229"/>
                    <measurement group_id="O2" value="110.82" spread="28.487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - LV Mass/End-diastolic Volume</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - LV Mass/End-diastolic Volume</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>g/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.696" spread="0.1437"/>
                    <measurement group_id="O2" value="0.687" spread="0.1163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline MRI Variables - LV Stroke Volume</title>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline MRI Variables - LV Stroke Volume</title>
          <population>Total number differs from Study totals due to subject non compliance with MRI (exam not completed)</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.05" spread="19.327"/>
                    <measurement group_id="O2" value="96.86" spread="21.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline Flow Mediated Dilatation (Reactive Hyperemia)</title>
        <description>Baseline in Flow Mediated Dilatation. The flow mediated dilatation metric is obtained using a device from Cordex, and a proprietary algorithm.
This metric represents the volume difference between a baseline arterial compliance curve and hyperemia arterial compliance curve in the positive transmural pressure region. This metric has a direct relationship to a subject's cardiovascular condition. Output range is 0-150. A higher score is indicative of a better flow mediated dilatation.</description>
        <time_frame>Baseline</time_frame>
        <population>Total number differs from Study totals due to subject non compliance with exam (exam not completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Flow Mediated Dilatation (Reactive Hyperemia)</title>
          <description>Baseline in Flow Mediated Dilatation. The flow mediated dilatation metric is obtained using a device from Cordex, and a proprietary algorithm.
This metric represents the volume difference between a baseline arterial compliance curve and hyperemia arterial compliance curve in the positive transmural pressure region. This metric has a direct relationship to a subject's cardiovascular condition. Output range is 0-150. A higher score is indicative of a better flow mediated dilatation.</description>
          <population>Total number differs from Study totals due to subject non compliance with exam (exam not completed)</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" spread="28.76"/>
                    <measurement group_id="O2" value="60.6" spread="30.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary Albumin to Creatinine Ratio (UACR)</title>
        <description>LS Mean Percentage Change (95% CI) from Baseline in UACR</description>
        <time_frame>From Baseline to 24 Weeks of Treatment</time_frame>
        <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
        <group_list>
          <group group_id="O1">
            <title>Verinurad 9 mg+Febuxostat 80 mg</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule administered orally, once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Albumin to Creatinine Ratio (UACR)</title>
          <description>LS Mean Percentage Change (95% CI) from Baseline in UACR</description>
          <population>Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations</population>
          <units>Precent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.40" lower_limit="-58.051" upper_limit="-9.535"/>
                    <measurement group_id="O2" value="21.40" lower_limit="-18.948" upper_limit="81.829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from time of signature of informed consent (Screening Visit) throughout the treatment period and including the follow-up period (Day 190).</time_frame>
      <desc>AEs were spontaneously reported by the patient or reported in response to an open question from the study site staff.</desc>
      <group_list>
        <group group_id="E1">
          <title>Verinurad 9 mg+Febuxostat 80 mg</title>
          <description>Capsule administered orally, once daily for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Capsule administered orally, once daily for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, version 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Troponin I Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wound Drainage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA, version 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The treatment code was broken for 3 patients.The effect of verinurad/febuxostat on sUA was underestimated as drug was administered after collection of blood samples.3 patients treated with verinurad/febuxostat had no detectable drug in PK samples.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Fredrik Erlandsson, Global Clinical Lead</name_or_title>
      <organization>AstraZeneca R&amp;D</organization>
      <phone>+46317762365</phone>
      <email>Fredrik.Erlandsson@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

